Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder

Journal of Urology

Volumn 191, Issue 3, 2014, Pages 830-841

  Xylinas, Evanguelos ^a,c,d   Cha, Eugene K ^a   Khani, Francesca ^a   Kluth, Luis A ^a,e   Rieken, Malte ^a,i   Volkmer, Björn G ^f   Hautmann, Richard ^g   Küfer, Rainer ^h   Chen, Yao Tseng ^a   Zerbib, Marc ^d   Rubin, Mark A ^a,b   Scherr, Douglas S ^a   Shariat, Shahrokh F ^a,j   Robinson, Brian D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d Institut Cochin   (France)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Hospital Kassel   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h Hospital Am Eichert   (Germany)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

carcinoma; oncofetal antigens; risk; urinary bladder; urothelium

Indexed keywords

CARCINOMA; ONCOFETAL ANTIGENS; RISK; URINARY BLADDER; UROTHELIUM;

AGED; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; GLYPICANS; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; RNA-BINDING PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENT; GLYPICAN 3; IMP3 PROTEIN; ONCOFETAL ANTIGEN; TPBG PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UROTHELIUM;

EID: 84893857460     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.08.048     Document Type: Article

References (27)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11
2. R.E. Hautmann, R.C. de Petriconi, and C. Pfeiffer et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients Eur Urol 61 2012 1039
3. S.F. Shariat, P.I. Karakiewicz, and G.S. Palapattu et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 176 2006 2414
4. J.P. Stein, G. Lieskovsky, and R. Cote et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666
5. M. Rink, E.K. Cha, and D. Green et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes Curr Urol Rep 13 2012 122
6. Y. Lotan, S.F. Shariat, and B.J. Schmitz-Dräger et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer Urol Oncol 28 2010 441
7. S.F. Shariat, M.W. Kattan, and A.J. Vickers et al. Statistical consideration for clinical biomarker research in bladder cancer Urol Oncol 28 2010 389
8. P.J. Southall, G.M. Boxer, and K.D. Bagshawe et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues Br J Cancer 61 1990 89
9. M. Monte, M. Simonatto, and L.Y. Peche et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents Proc Natl Acad Sci U S A 103 2006 11160
10. N. Yamauchi, A. Watanabe, and M. Hishinuma et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma Mod Pathol 18 2005 1591
11. E.R. Boghaert, L. Sridharan, and K.M. Khandke et al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin Int J Oncol 32 2008 221
12. S.F. Shariat, P.I. Karakiewicz, and G. Godoy et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study Clin Cancer Res 15 2009 7012
13. L. Sitnikova, G. Mendese, and Q. Liu et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder Clin Cancer Res 14 2008 1701
14. L. Dyrskjøt, K. Zieger, and T. Kissow Lildal et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma Br J Cancer 107 2012 116
15. M. Rink, K. Park, and B.G. Volkmer et al. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy Urol Oncol 31 2013 1716
16. M. Rink, H. Fajkovic, and E.K. Cha et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma Eur Urol 61 2012 854
17. T. Szarvas, F. vom Dorp, and C. Niedworok et al. High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer BJU Int 110 2012 E308
18. A.O. Gure, R. Chua, and B. Williamson et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer Clin Cancer Res 11 2005 8055
19. D. Perez, F. Hauswirth, and D. Jäger et al. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors Int J Cancer 128 2011 2947
20. P.I. Karakiewicz, S.F. Shariat, and G.S. Palapattu et al. Precystectomy nomogram for prediction of advanced bladder cancer stage Eur Urol 50 2006 1254
21. E. Xylinas, E.K. Cha, and M. Sun et al. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling Br J Cancer 107 2012 1826
22. S.F. Shariat, S. Pahlavan, and A.G. Baseman et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder Urology 57 2001 60
23. S.F. Shariat, A.R. Zlotta, and R. Ashfaq et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness Mod Pathol 20 2007 445
24. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Eur Urol 48 2005 189
25. K. Kono, Y. Mizukami, and Y. Daigo et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer Cancer Sci 100 2009 1502
26. Amato RJ and M. Stepankiw: Clinical efficacy of TroVax in the treatment of progressive castration-resistant prostate cancer. Clin Med Insights Oncol 2012; 6: 67.
27. R.T. Zhang, S.D. Bines, and C. Ruby et al. TroVax(®) vaccine therapy for renal cell carcinoma Immunotherapy 4 2012 27